NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading ...

Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...

Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...

Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer. This ...

The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

The FDA has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneous, chemo-free ...

After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in patients on immunotherapy and targeted drugs: a dramatic initial response, then ...